Topics
Dexrazoxane cardioprotection
Childhood cancer survivors are at risk for anthracycline-induced cardiotoxicity, which may be prevented by dexrazoxane. We have developed recommendations for dexrazoxane administration in children with cancer expected to receive anthracyclines.